OLEMA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $22.87 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $25.53, a 466.08% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $4.51, a 70.41% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $15.24, a 218.16% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $4.79, a 32.25% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.06, a 64.39% decline from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $14.21, a 140.03% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.92, a 7.05% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.53, a 83.65% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.87 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $25.53 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $5.06 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $4.54 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $4.46 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $4.51 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $14.21 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $14.35 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $14.56 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $15.24 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $5.92 10-K · filed 2024-03-11 | |||
| 2023-09-30 | $5.24 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $4.98 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $4.79 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $5.53 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $6.57 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $6.73 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $7.07 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $33.82 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $35.88 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $37.12 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $45.79 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |